Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Zhenlong Li *Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.ORCID 0009-0005-1171-4070
Rui Ma *Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.
Hejun TangDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.
Ningyuan LiuDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.
Jianying ZhangDepartment of Computational and Quantitative Medicine, City of Hope National Medical Center, Los Angeles, CA, USA.
Guido MarcucciDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-3983-5908
Michael A CaligiuriDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Los Angeles, CA, USA. mcaligiuri@coh.org.ORCID 0000-0002-4095-3020
Jianhua YuDivision of Hematology & Oncology, Department of Medicine, School of Medicine, University of California, Irvine, CA, USA. jianhuay@uci.edu.ORCID 0000-0002-0326-3223
Funding
China Postdoctoral Science FundFoundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) AI129582Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA163205Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA210087Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA223400Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA247550Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA264512Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA265095Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) CA266457Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.) NS106170
6 · The paper itself
Abstract
Innate lymphoid cells (ILCs) are crucial for cancer immunosurveillance. While mouse type 1 ILCs (ILC1s) control acute myeloid leukemia (AML) by targeting leukemia stem cells (LSCs), the role of human ILC1s in AML remains largely undefined. Here, we find that ILC1s in AML patients are impaired, with reduced total ILC1 numbers and diminished function. In contrast, healthy donor (HD) ILC1s-derived TNFα inhibits the leukemic transition from CD34
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development. · full record | OpenQuestion